Trial Profile
Docetaxel and Cetuximab in Patients With Docetaxel-resistant Hormone-refractory Prostate Cancer (HRPC). A Multicenter Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 25 Jun 2012 Actual end date Apr 2010 added as reporetd by ClinicalTrials.gov.
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.